文献速递肺外科

机器人辅助肺叶切除术治疗非小细胞肺癌的成本效果分析

Cost-Effectiveness Analysis of Robotic-assisted Lobectomy for Non-Small Cell Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2021-08-10

本研究采用决策分析模型,从医疗保健和社会两个视角比较机器人辅助肺叶切除术(RAL)、电视辅助胸腔镜手术(VATS)和开胸肺叶切除术治疗可切除非小细胞肺癌的成本效果,时间跨度1年。结果显示开胸手术相比RAL和VATS不具成本效果;在较低支付意愿阈值下RAL相比VATS不具成本效果,但降低机器人器械成本、缩短手术时间、降低中转率、缩短住院时间、提高医院手术量及改善生活质量等因素可能使RAL更具成本效果。

要点

  • 开胸肺叶切除术相比RAL和VATS不具成本效果。

核心结论

  • 在较低支付意愿阈值下,RAL相比VATS对肺癌肺叶切除术不具成本效果。
  • 若干因素可能推动RAL成为更具成本效果的微创肺癌切除方式。

研究设计与样本

  • 采用决策分析模型,比较RAL、VATS和开胸肺叶切除术的成本效果,时间跨度1年,从医疗保健和社会两个视角进行分析。
  • 比较各术式的医疗保健成本(2020年美元)和质量调整生命年,计算每获得一个质量调整生命年的增量成本效果比。
  • 进行敏感性分析以识别在多个支付意愿阈值下驱动成本效果的因素。

主要发现

  • 开胸手术相比RAL和VATS均不具成本效果。
  • 机器人器械成本略低、手术室时间更短、中转率更低、住院时间更短、医院手术量更高及生活质量改善时,RAL变得具成本效果。
  • 若外科医生能利用机器人技术提高微创肺叶切除术的比例,RAL也具成本效果。

临床怎么用

  • 在较低支付意愿阈值下,选择RAL替代VATS需考虑成本效果。
  • 通过降低机器人器械成本、缩短手术时间和住院时间、降低中转率等措施可能改善RAL的成本效果。
  • 提高医院手术量和微创肺叶切除术比例可能使RAL更具成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Robot-assisted thoracic surgery has emerged as an alternative to video-assisted thoracic surgery (VATS) for treating patients with resectable non-small cell lung cancer. The objective of this study was to evaluate the cost effectiveness of robotic-assisted lobectomy (RAL) compared with VATS and open lobectomy for adults with NSCLC. METHODS: A decision analysis model was employed to compare the cost effectiveness of RAL, VATS, and open lobectomy with 1-year time horizon from both health care and societal perspectives. Health care costs (2020$) and quality-adjusted life-years were compared between the approaches. The incremental cost-effectiveness ratio was calculated in terms of cost per quality-adjusted life-years gained. Sensitivity analyses were performed to identify variables driving cost effectiveness across several willingness-to-pay thresholds. RESULTS: Open thoracotomy was not cost effective compared with both RAL and VATS lobectomy. From the health care sector perspective, RAL was $394.97 more expensive per case than VATS resulting in an incremental cost-effectiveness ratio of $180 755.10 per quality-adjusted life-year. From the societal perspective, RAL was $247.77 more expensive per case than VATS, resulting in an incremental cost-effectiveness ratio of $113 388.80 per quality-adjusted life-years. Robotic-assisted lobectomy becomes cost effective with marginally lower robotic instrument costs, shorter operating room times, lower conversion rates, shorter lengths of stay, higher hospital volumes, and improved quality of life. Robotic-assisted lobectomy is also cost effective if surgeons can increase the proportion of minimally invasive lobectomies using robotic technology. CONCLUSIONS: Compared with VATS, RAL is not cost effective for lung cancer lobectomy at lower willingness-to-pay thresholds. However, several factors may drive RAL to emerge as the more cost-effective approach for minimally invasive lung cancer resection.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Heiden BT, Mitchell JD, Rome E, et al. Cost-Effectiveness Analysis of Robotic-assisted Lobectomy for Non-Small Cell Lung Cancer. Ann Thorac Surg. 2021. PMID: 34389311. doi:10.1016/j.athoracsur.2021.06.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。